SEC Comment Letter 0000000000-24-007721 to FIBROGEN INC (FGEN) (CIK 0000921299) (KYNB)
FIBROGEN INC (FGEN) (CIK 0000921299)
Date: July 9, 2024 · CIK: 0000921299 · Accession: 0000000000-24-007721
AI Filing Summary & Sentiment
File numbers found in text: 333-280597
Letter
July 8, 2024 Thane Wettig Chief Executive Officer FibroGen, Inc. 409 Illinois Street San Francisco, California 94158 Re:FibroGen, Inc. Registration Statement on Form S-3 Filed June 28, 2024 File No. 333-280597 Dear Thane Wettig: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:John McKenna, Esq.
Show Raw Text
July 8, 2024
Thane Wettig
Chief Executive Officer
FibroGen, Inc.
409 Illinois Street
San Francisco, California 94158
Re:FibroGen, Inc.
Registration Statement on Form S-3
Filed June 28, 2024
File No. 333-280597
Dear Thane Wettig:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:John McKenna, Esq.